尤瑞克林治疗溶栓时间窗外中青年人进展性脑梗死的疗效观察

Observation of the efficacy of Eureklin in the treatment of progressive cerebral infarction in young and middle-aged people outside the thrombolytic time window

目的观察应用开放侧支循环药物尤瑞克林治疗溶栓时间窗外(发病时间大于6h)中青年人进展性脑梗死的临床疗效.方法选择2016年3月至2019年3月在汕头潮南民生医院神经内科住院治疗的溶栓时间窗外的中青年进展性脑梗死患者120例,患者均经头颅CT或MRI证实.采用随机抽签方法分为对照组和治疗组.应用临床常规治疗为对照组(60例)及在临床常规治疗基础上加用尤瑞克林静脉滴注为治疗组(60例).治疗前及治疗14 d后应用美国国立卫生研究院卒中量表(NIHSS)、日常生活能力量表(ADL)评估患者的神经功能缺损状况及日常生活活动能力指数(Barthel指数),同时观察药物不良反应.结果治疗后治疗组的NIHSS评分[(3.4±0.3)分]低于对照组[(4.1±0.4)分],治疗组的ADL评分[(67.5±24.8)分]高于对照组[(57.8±26.7)分],差异均有统计学意义(t=0.014、0.003,均P<0.05);治疗组总有效率[83.33%(50/60)]高于对照组[71.67%(43/60)],差异有统计学意义(x2=3.596,P<0.05),同时治疗组未发生严重不良反应.结论溶栓时间窗外的中青年进展性脑梗死患者应用尤瑞克林能改善患者的神经功能缺损症状,提高日常生活能力,而且未发生出血等严重不良事件,值得临床推广应用.

Objective To observe the clinical efficacy of Eureklin in the treatment of progressive cerebral infarction in young and middle-aged people outside the thrombolytic time window(the onset time was more than 6h).Methods From March 2016 to March 2019,120 young and middle-aged patients with progressive brain infarction who admitted to the neurology department of Chaonan Minsheng Hospital were selected and all patients were confirmed by cranial CT or MRI.They were divided into two groups by random drawing method.Clinical conventional therapy was applied in the control group(60 cases),and on the basis of conventional treatment,Eureklin intravenous drips was used in the treatment group(60 cases).Before and after treatment 14d,the national institutes of health stroke scale(NIHSS),daily living ability scale(ADL)were used to assessment of neurological impairment and Barthel index in patients.At the same time,the drug side effects and adverse reactions were observed.Results After treatment,the NIHSS score in the conventional treatment group[(3.4±0.3)points]was lower than that in the Eureklin group[(4.1±0.4)points],and the ADLscore in the conventional treatment group[(67.5±24.8)points]was higher than that in the Eureklin group[(57.8±26.7)points],the difference was statistically significant(t=0.014,0.003,all P<0.05).The total effective rate of the treatment group[83.33%(50/60)]was higher than that of the control group[71.67%(43/60)],the difference was statistically significant(χ2=3.596,P<0.05).At the same time,no serious adverse reactions were found in the Eureklin treatment group.Conclusion For young and middle-aged patients with progressive cerebral infarction outside the thrombolytic time window,the application of Eureklin can improve the patients*symptoms of neurological dysfunction,improve the ability of daily life,and without serious adverse events such as bleeding,which is worthy of clinical application.